Cargando…

Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China

OBJECTIVE: To determine the cost effectiveness of molecular monitoring in patients with chronic myeloid leukemia in the chronic phase (CML-CP) compared to no molecular monitoring from a Chinese payer perspective. METHODS: Analyses were conducted using a semi-Markov model with a 50-year time horizon....

Descripción completa

Detalles Bibliográficos
Autores principales:	Maheshwari, Vikalp Kumar, Slader, Cassandra, Dani, Nidhi, Gkitzia, Christina, Yuan, Quan, Xiong, Tengbin, Liu, Yu, Viana, Ricardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544861/ https://www.ncbi.nlm.nih.gov/pubmed/34695169 http://dx.doi.org/10.1371/journal.pone.0259076

Ejemplares similares

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey
por: Uhm, Jieun, et al.
Publicado: (2021)

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
por: Atallah, Ehab, et al.
Publicado: (2023)

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia
por: Kim, Kibum, et al.
Publicado: (2019)

Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
por: Wang, Xiao Jun, et al.
Publicado: (2022)

Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
por: Réa, Delphine, et al.
Publicado: (2023)

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
por: Ong, Jian Chun Matthew, et al.
Publicado: (2023)

Reduced Diabetes Mellitus-related Comorbidities by Regular Self-monitoring of Blood Glucose: Economic and Quality of Life Implications
por: Mohan, Viswanathan, et al.
Publicado: (2018)

Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis
por: Shen, Kunling, et al.
Publicado: (2016)

The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia
por: Conti, Rena M, et al.
Publicado: (2021)

P424: LANDSCAPE OF CHROMATIN ACCESSIBILITY IN ACUTE MYELOID LEUKEMIA
por: Ochi, Yotaro, et al.
Publicado: (2023)

Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
por: Men, Peng, et al.
Publicado: (2018)

P112 Non-invasive ventilation in motor neurone disease, an audit of a tertiary centers practice
por: Slader, S
Publicado: (2022)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions
por: Meillon-Garcia, Luis Antonio, et al.
Publicado: (2020)

Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients
por: Yamazaki, Kiyotaka, et al.
Publicado: (2020)

Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia
por: Sharma, Amit, et al.
Publicado: (2020)

Is karyotyping still needed in the diagnosis and monitoring of chronic myeloid leukemia?
por: Chauffaille, Maria de Lourdes L.F.
Publicado: (2017)

Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia
por: Morakinyo, Oluwatobiloba, et al.
Publicado: (2022)

What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?
por: Bosi, Guilherme Rasia, et al.
Publicado: (2019)

Interpreting Molecular Monitoring Results and International Standardization in Chronic Myeloid Leukemia
por: Bauer, Stephanie, et al.
Publicado: (2012)

Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

Cryo-EM, Protein Engineering, and Simulation Enable the Development of Peptide Therapeutics against Acute Myeloid Leukemia
por: Zhang, Kaiming, et al.
Publicado: (2022)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA
por: Thakral, Deepshi, et al.
Publicado: (2020)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

Recent developments in immunotherapy of acute myeloid leukemia
por: Lichtenegger, Felix S., et al.
Publicado: (2017)

Successful treatment of chronic myeloid leukemia with tyrosine kinase inhibitors goes beyond access to drugs
por: Conchon, Monika
Publicado: (2013)

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
por: Arenaza, Ainhoa, et al.
Publicado: (2019)

Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia
por: Pandya, Bhavik J, et al.
Publicado: (2021)

Acute Myeloid Leukemia
Publicado: (2019)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

Acute myeloid leukemia
por: Ossenkoppele, Gert
Publicado: (2018)

Chronic myeloid leukemia
por: Sauβele, Susanne
Publicado: (2018)

Bioinformatics and Raman spectroscopy-based identification of key pathways and genes enabling differentiation between acute myeloid leukemia and T cell acute lymphoblastic leukemia
por: Liang, Haoyue, et al.
Publicado: (2023)

Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a
por: Shields, Benjamin J., et al.
Publicado: (2016)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches
por: Izzo, Barbara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c1qicvo94544pceqcs0789996s